In vitro evaluation of antifungal potential of imidazolium salts against Candida albicans
DOI:
https://doi.org/10.22456/2177-0018.113536Keywords:
Candida albicans, Antifungal agents, Ionic liquidsAbstract
Aim: This study aims to evaluate the antifungal potential of imidazolium salts (IS) against Candida albicans. Material and methods: Antifungal evaluation of the IS was performed using the disk diffusion test, using a strain of Candida albicans (ATCC 90028). Five different IS were synthesized and tested in the present study: 1,8-bis(methylimidazolium-1-yl) octane bromide (MImC8MImBr2), 1,12-bis(methylimidazolium-1-yl) dodecane methanesulfonate (MImC12MIm(MeS)2), 1-n-hexadecyl-2,3-dimethylimidazolium chloride (C16DMImCl), 1,10-bis(methylimidazolium-1-yl) decane methanesulfonate (MImC10MIm(MeS)2) e 1,10-bis(methylimidazolium-1-yl) decane bromide (MImC10MImBr2). Cetylpyridinium chloride (C16PyrCl) was used as a reference substance. Chlorhexidine (C34H54Cl2N10O14) and saline (NaCl 0,9%) solutions were positive and negative controls, respectively. Results: Among the tested IS, MImC12MIm(MeS)2, MImC10MIm(MeS)2 and MImC10MImBr2 showed the following values for inhibition halos: 28,00 mm, 20,50 mm and 18,75 mm, respectively. These values were similar or superior than those found for the positive control (14.87 mm) and reference (0 mm) substances. Discussion: IS can be a promising alternative to antifungal conventional therapies, as exemplified in previous studies. However, further in vitro and in vivo studies are needed to assess the antifungal potential of these compounds against Candida-mixed biofilms. Conclusion: Based on these results, there are three in vitro promising antifungal potential against Candida albicans IS tested in this study.Downloads
References
Epstein JB. Antifungal therapy in oropharyngeal mycotic infections. Oral Surgery, Oral Medicine, Oral Pathology. 1990 Jan;69(1):32-41.
Stramandinoli RT, Souza PHC, Westphalen FH, Bisinelli JC, Ignácio SA, Yurgel LS. Prevalência de candidose bucal em pacientes hospitalizados e avaliação dos fatores de risco. RSBO (Online). 2010 Mar 1;7(1):66-72.
Cannon RD, Chaffin WL. Oral colonization by candida albicans. Critical Reviews in Oral Biology & Medicine. 1999 Jun;10(3):359-83.
Akpan A. Oral candidiasis. Postgraduate Medical Journal [Internet]. 2002 Aug;78(922):455-9.
Simões RJ, Fonseca P, Figueiral MH. Infecções por Candida spp na cavidade oral. Odontologia Clínico-Científica. 2013 Mar;12(1):19-22.
Pereira JM, Paiva JA. Tratamento da candidíase invasiva no doente crítico. Revista Portuguesa de Medicina Intensiva. 2010;17(1):23-30.
Neto MM, Danesi CC, Unfer DT. Candidíase Bucal. Saúde. 2005;31(1-2):16-26.
Canuto MM, Rodero FG. Antifungal drug resistance to azoles and polyenes. The Lancet Infectious Diseases. 2002 Sept; 2(9):550-63.
Mukherjee P, Sheehan D, Puzniak L, Schlamm H, Ghannoum M. Echinocandins: are they all the same? Journal of Chemotherapy. 2011 Dec;23(6):319-25.
Anderson EB, Long TE. Imidazole- and imidazolium-containing polymers for biology and material science applications. Polymer. 2010 May;51(12):2447-54.
Dalla Lana DF, Donato RK, Bündchen C, Guez CM, Bergamo VZ, de Oliveira LFS, et al. Imidazolium salts with antifungal potential against multidrug-resistant dermatophytes. Journal of Applied Microbiology. 2015 Jun;119(2):377-88.
Schrekker HS, Donato RK, Fuentefria AM, Bergamo V, Oliveira LF, Machado MM. Imidazolium salts as antifungal agents: activity against emerging yeast pathogens, without human leukocyte toxicity. MedChemComm. 2013 Oct;4(11):1457-60.
Reddy GKK, Nancharaiah YV. Alkylimidazolium ionic liquids as antifungal alternatives: antibiofilm activity against candida albicans and underlying mechanism of action. Frontiers in Microbiology. 2020 Apr;11:730.
Lee H, Woo ER, Lee DG. Apigenin induces cell shrinkage in Candida albicans by membrane perturbation. FEMS Yeast Research. 2018 Feb;18(1). doi: 10.1093/femsyr/foy003.
Ocakoglu K, Tasli H, Limoncu MH, Lambrecht FY. Synthesis and antimicrobial activity of imidazolium salts. Trends in Cancer Research and Chemotherapy. 2018 1: doi: 10.15761/TCRC.1000103.
Fonseca E, Demétrio da Silva V, Klitzke JS, Schrekker HS, Amico SC. Imidazolium ionic liquids as fracture toughening agents in DGEBA-TETA epoxy resin. Polymer Testing. 2020 87:106556.
Cornellas A, Perez L, Comelles F, Ribosa I, Manresa A, Garcia MT. Self-aggregation and antimicrobial activity of imidazolium and pyridinium based ionic liquids in aqueous solution. Journal of Colloid and Interface Science. 2011 Mar;355(1):164-71.
Costa ACBP, Pereira CA, Freire F, Junqueira JC, Jorge AOC. Methods for obtaining reliable and reproducible results in studies of Candida biofilms formed in vitro. Mycoses. 2013 May;56(6):614-22.
Fu J, Wei P, Zhao C, He C, Yan Z, Hua H. In vitro antifungal effect and inhibitory activity on biofilm formation of seven commercial mouthwashes. Oral Diseases. 2014 Nov;20(8):815-20.
Ardizzoni A, Pericolini E, Paulone S, Orsi CF, Castagnoli A, Oliva I, et al. In vitro effects of commercial mouth washes on several virulence traits of Candida albicans, viridans streptococci and Enterococcus faecalis colonizing the oral cavity. Sturtevant J, editor. PLOS ONE. 2018 Nov 15;13(11):e0207262.
Barbour M, Maddocks S, Wood N, Collins A. Synthesis, characterization, and efficacy of antimicrobial chlorhexidine hexametaphosphate nanoparticles for applications in biomedical materials and consumer products. International Journal of Nanomedicine ;8:3507-19.
Lobo CIV, Rinaldi TB, Christiano CMS, De Sales Leite L, Barbugli PA, Klein MI. Dual-species biofilms of Streptococcus mutans and Candida albicans exhibit more biomass and are mutually beneficial compared with single-species biofilms. Journal of Oral Microbiology. 2019 Mar;11(1):1581520.
Souza JGS, Bertolini M, Thompson A, Mansfield JM, Grassmann AA, Maas K, et al. Role of glucosyltransferase R in biofilm interactions between Streptococcus oralis and Candida albicans. The ISME Journal. 2020 May;14(5):1207-1222.
Downloads
Published
How to Cite
Issue
Section
License
All articles published in this journal adhere to Creative Commons License Attributions 4.0 (CC BY 4.0), and its use must be ruled by its licensed means. Authors are allowed to agree to additional and separate contracts for the non-exclusive distribution of the article published in this journal, such as publishing in an institutional repository, as long as the article has a recognition of authorship and first publication in this journal.
